natgillin/translations-raw huggingface dataset:
One main study involving patients with chronic kidney disease who had hyperkalaemia found that Veltassa is effective in reducing potassium levels in the blood. 
V glavni študiji, ki je vključevala bolnike s kronično ledvično boleznijo, ki so imeli hiperkaliemijo, so ugotovili, da je zdravilo Veltassa učinkovito pri zniževanju ravni kalija v krvi.
After 4 weeks, the average potassium level did not change in patients who received Veltassa for 4 weeks but it went back up by an average of 0.7 mmol/litre in patients who received placebo. 
Po štirih tednih se povprečna raven kalija pri bolnikih, ki so štiri tedne prejemali zdravilo Veltassa, ni spremenila, pri bolnikih, ki so prejemali placebo, pa se je dvignila za povprečno 0,7 mmol/liter.
For practical information about using Veltassa, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Veltassa naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
The second part of the study compared Veltassa with placebo (a dummy treatment) in 107 patients whose potassium level had fallen with Veltassa treatment during the first part of the study. 
V drugem delu študije so primerjali zdravilo Veltassa s placebom (zdravilom brez zdravilne učinkovine) pri 107 bolnikih, pri katerih se je raven kalija med zdravljenjem z zdravilom Veltassa v prvem delu študije znižala.
When Veltassa is taken by mouth, the active substance, patiromer, remains in the gut where it attaches tightly to potassium to form a compound that is then passed out in the stool. 
Ob peroralnem jemanju zdravila Veltassa zdravilna učinkovina patiromer ostane v črevesu, kjer se trdno veže na kalij in tvori spojino, ki se nato izloči z blatom.
In the first part of the study, 243 patients with hyperkalaemia (with average potassium level of 5.6 mmol/litre) were treated with Veltassa. 
V prvem delu študije so z zdravilom Veltassa zdravili 243 bolnikov s hiperkaliemijo (s povprečnimi ravnmi kalija 5,6 mmol/liter).
Veltassa is a medicine used for treating adults with high levels of potassium in the blood (hyperkalaemia). 
Zdravilo Veltassa se uporablja za zdravljenje visokih ravni kalija v krvi (hiperkaliemije) pri odraslih.
For the full list of all side effects and restrictions with Veltassa, see the package leaflet. 
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Veltassa glejte navodilo za uporabo.
The doctor then adjusts the dose at intervals of at least one week, based on the patient's blood levels of potassium. 
Zdravnik nato enkrat tedensko prilagaja odmerek glede na raven kalija v bolnikovi krvi.
The Agency considered that there is a need for effective treatment of hyperkalaemia and Veltassa achieves a meaningful lowering of potassium levels. 
Agencija je presodila, da obstaja potreba po učinkovitem zdravljenju hiperkaliemije, in z zdravilom Veltassa se ravni kalija pomembno znižajo.
Veltassa contains the active substance patiromer. 
Zdravilo Veltassa vsebuje zdravilno učinkovino patiromer.
How does Veltassa work? 
Kako zdravilo Veltassa deluje?
How is Veltassa used? 
Kako se zdravilo Veltassa uporablja?
3 bottles 
3 plastenke
Route of administration Immediate Packaging Content (concentration) Pack size 
Stična ovojnina vsebina (koncentracija)
(Invented) name Strength 
Številka (EU) dovoljenja za promet (Izmišljeno) ime Jakost
This overview was last updated in March 2019. 
Povzetek je bil nazadnje posodobljen marca 2019.
This medicine is the same as NexGard, which is already authorised in the European Union (EU). 
To zdravilo je enako zdravilu NexGard, ki je že odobreno v Evropski uniji (EU).
The blister with the remaining chewable tablets should be returned into the carton. 
Pretisni omot s preostalimi žvečljivimi tabletami je treba vrniti v škatlo.
The appropriate strength of tablets to be given is determined based on the dog's bodyweight. 
Ustrezna jakost tablete, ki jo je treba dati, se določi na podlagi telesne mase psa.
People handling the medicine should wash their hands after handling the product. 
Osebe, ki rokujejo z zdravilom, si morajo po rokovanju z njim umiti roke.
In order for the active substance to have an effect, fleas and ticks must attach to the skin and start feeding on the dog's blood. 
Da lahko učinkovina deluje, se morajo bolhe in klopi pritrditi na kožo in se začeti hraniti s krvjo psa.
Further information on Afoxolaner Merial can be found on the Agency's website: ema.europa.eu/medicines/veterinary/EPAR/afoxolaner-merial. 
Nadaljnje informacije o zdravilu Afoxolaner Merial so na voljo na spletni strani agencije: ema.europa.eu/medicines/veterinary/EPAR/felisecto-plus.
Afoxolaner Merial received a marketing authorisation valid throughout the EU on 20 May 2019. 
Zdravilo Afoxolaner Merial je pridobilo dovoljenje za promet, veljavno po vsej Evropski uniji, 20. maja 2019.
This results in uncontrolled activity of the nervous system and the paralysis and death of fleas, ticks and mites. 
S tem povzroči nenadzorovano delovanje živčnega sistema ter paralizo in smrt bolh, klopov in garjavcev.
The European Medicines Agency decided that Afoxolaner Merial's benefits are greater than its risks and it can be authorised for use in the EU. 
Evropska agencija za zdravila je odločila, da so koristi zdravila Afoxolaner Merial večje od z njim povezanih tveganj, in da se lahko odobri za uporabo v EU.
Because parasites must start feeding on the dog in order to be killed by the medicine, there may be a risk of transmission of diseases with which they may be infected. 
Ker se morajo zajedavci začeti hraniti s krvjo psa, da bi jih zdravilo lahko uničilo, ni mogoče izključiti tveganja za prenos bolezni, s katerimi so ti zajedavci lahko okuženi.
Only one chewable tablet at a time should be removed from the blister to prevent children from accessing the product. 
Iz pretisnega omota odstranite le eno žvečljivo tableto naenkrat, da bi preprečili otrokom morebiten dostop do tega zdravila.
This means that it kills parasites that live on or in the skin or in the fur of animals, such as fleas, ticks and mites. 
To pomeni, da uničuje zajedavce, ki živijo na koži ali v dlaki živali, kot so bolhe, klopi in garjavci.
Afoxolaner kills fleas before they can lay eggs and so helps to reduce contamination of the dogs' environment. 
Afoksolaner ubije bolhe, preden izležejo jajčeca, s čimer pomaga zmanjšati kontaminacijo okolice psa.
Afoxolaner kills parasites by causing over-stimulation of their nervous system. 
Afoksolaner zajedavce ubije tako, da pretirano stimulira njihov živčni sistem.
It may be used as part of the management of flea allergy dermatitis (an allergic reaction to flea bites). 
Uporablja se lahko kot del zdravljenja alergijskega dermatitisa, ki ga povzročajo bolhe (alergijske reakcije na ugrize bolh).
Treatment should be repeated at monthly intervals during the flea or tick seasons, monthly for demodectic mange until the mange is successfully treated (as confirmed by two negative skin scrapings one month apart) and monthly for two months for sarcoptic mange, or longer if treatment is unsuccessful as indicated by clinical signs and skin scrapings. 
Zdravljenje je treba ponavljati v mesečnih razmikih vso sezono bolh/klopov, enkrat mesečno pri garjavosti vrste Demodex canis, dokler ni uspešno pozdravljena (in potrjena z negativnimi rezultati dveh kožnih ostružkov, vzetih v enomesečnem razmiku), ter enkrat mesečno dva zaporedna meseca pri garjavosti vrste Sarcoptes scabiei oziroma dlje, če klinični znaki in ostružki kože nakazujejo, da zdravljenje ni bilo uspešno.
Afoxolaner Merial kills fleas within 8 hours and ticks within 48 hours. 
Zdravilo Afoxolaner Merial bolhe ubije v osmih urah, klope pa v 48 urah.
The effectiveness of Afoxolaner Merial was investigated in both laboratory and field studies. 
Učinkovitost zdravila Afoxolaner Merial so proučevali v laboratorijskih in terenskih študijah.
The company that makes NexGard has agreed that its scientific data can be used for Afoxolaner Merial (‘informed consent'). 
Podjetje, ki proizvaja zdravilo NexGard, se strinja, da se lahko znanstveni podatki o tem zdravilu uporabijo tudi za zdravilo Afoxolaner Merial („uporaba dokumentacije s soglasjem“).
For more information about using Afoxolaner Merial, see the package leaflet or contact your veterinarian or pharmacist. 
Za več informacij glede uporabe zdravila Afoxolaner Merial glejte navodilo za uporabo ali se posvetujte z veterinarjem ali farmacevtom.
Afoxolaner Merial reduced the number of fleas and ticks by at least 98% and was at least as effective as a spot-on medicine containing pyriprole (another medicine against fleas and ticks). 
Zdravilo Afoxolaner Merial je zmanjšalo število bolh in klopov za vsaj 98 % ter je bilo vsaj tako učinkovito kot zdravilo za kožni nanos, ki vsebuje piriprol (drugo zdravilo proti bolham in klopom).
This authorisation was based on the authorisation granted to NexGard in 2014 (‘informed consent'). 
Izdaja tega dovoljenja je temeljila na dovoljenju za promet z zdravilom NexGard, ki je bilo izdano leta 2014 (uporaba dokumentacije s soglasjem).
In an EU field study involving 146 dogs with flea and/or tick infestations, a single treatment with Afoxolaner Merial was effective in treating flea and tick infestations in dogs for up to 30 days after treatment. 
V terenski študiji, ki so jo opravili v EU in v katero so vključili 146 psov z bolhami in/ali klopi, je bilo eno samo zdravljenje z zdravilom Afoxolaner Merial učinkovito proti bolham in klopom pri psih, kar je trajalo še do 30 dni po zdravljenju.
After being given, its actions last for at least 5 weeks against fleas and up to one month against ticks. 
Po uporabi zdravilo proti bolham deluje najmanj pet tednov, proti klopom pa do enega meseca.
An overview of Afoxolaner Merial and why it is authorised in the EU 
Pregled zdravila Afoxolaner Merial in zakaj je odobreno v EU
Afoxolaner Merial is available as chewable tablets in four different strengths for use in dogs of different weights. 
Zdravilo Afoxolaner Merial je na voljo v obliki žvečljivih tablet v štirih različnih jakostih, namenjenih za uporabo pri psih z različno telesno maso.
Afoxolaner Merial reduced the number of live mites by 97% 56 days after starting treatment and by 98% 84 days after starting treatment. 
Zdravilo Afoxolaner Merial je v 56 dneh po začetku zdravljenja zmanjšalo število živih garjavcev za 97%, 84 dni po začetku zdravljenja pa za 98%.
It blocks the normal movement of charged chloride particles (ions) in and out of nerve cells, especially those nerves that 
Zavira normalno gibanje nabitih kloridnih delcev (ionov) v živčnih celicah in iz njih, zlasti tistih živcev, ki proizvajajo gama-aminomasleno kislino (GABA) za uravnavanje živčnega sistema.
Other information about Afoxolaner Merial 
Druge informacije o zdravilu Afoxolaner Merial
Why is Afoxolaner Merial authorised in the EU? 
Zakaj je zdravilo Afoxolaner Merial odobreno v EU?
Afoxolaner Merial is a veterinary medicine used to treat infestations with fleas and ticks, as well as demodectic and sarcoptic mange (skin infestations caused by two different types of mites) in dogs. 
Afoxolaner Merial je zdravilo za uporabo v veterinarski medicini, ki je namenjeno zdravljenju infestacij z bolhami in klopi ter garjavosti vrste Demodex canis in Sarcoptes scabiei (kožne garjavosti, ki jo povzročata dve vrsti garjavcev) pri psih.
What is Afoxolaner Merial and what is it used for? 
Kaj je zdravilo Afoxolaner Merial in za kaj se uporablja?
A second EU field study involved 31 dogs with demodectic mange which were treated monthly on 3 occasions with Afoxolaner Merial. 
V drugo terensko študijo, opravljeno v EU, so vključili 31 psov z garjavostjo vrste Demodex canis, ki so jih trikrat zapored enkrat mesečno zdravili z zdravilom Afoxolaner Merial.
What are the risks associated with Afoxolaner Merial? 
Kakšna tveganja so povezana z zdravilom Afoxolaner Merial?
Afoxolaner Merial reduced the number of live mites by 96% 28 days after starting treatment and by 100% 56 days after starting treatment. 
Zdravilo Afoxolaner Merial je v 28 dneh po začetku zdravljenja zmanjšalo število živih garjavcev za 96%, 56 dni po začetku zdravljenja pa za
The active substance in Afoxolaner Merial, afoxolaner, acts as an ‘ectoparasiticide'. 
Učinkovina v zdravilu Afoxolaner Merial, afoksolaner, deluje kot ektoparaziticid.
What benefits of Afoxolaner Merial have been shown in studies? 
Kakšne koristi je zdravilo Afoxolaner Merial izkazalo v študijah?
A third EU field study involved 38 dogs with sarcoptic mange which were treated monthly for two months with Afoxolaner Merial. 
V tretjo terensko študijo so vključili 38 psov z garjavostjo vrste Sarcoptes scabiei, ki so zdravilo Afoxolaner Merial prejeli enkrat na mesec dva meseca zapored.
Afoxolaner Merial contains the active substance afoxolaner. 
Zdravilo Afoxolaner Merial vsebuje učinkovino afoksolaner.
How is Afoxolaner Merial used? 
Kako se zdravilo Afoxolaner Merial uporablja?
How does Afoxolaner Merial work? 
Kako zdravilo Afoxolaner Merial deluje?
List of the names, pharmaceutical form, strengths of the medicinal product, route of administration, applicants / marketing authorisation holder in the Member States 
Seznam imen, farmacevtskih oblik, jakosti zdravil, poti uporabe zdravila, predlagateljev, imetnikov dovoljenja za promet z zdravilom v državah članicah
• Wash your hands 
• Umijte si roke.
(picture 3) 
(slika 3).
Date of first authorisation: 27 November 2001 Date of latest renewal: 06 October 2006 
Datum prve odobritve: 27. november 2001 Datum zadnjega podaljšanja: 06. oktober 2006
If a drop misses the eye, try again. 
Če kapljica zgreši oko, poskusite ponovno.
Now turn over 
Obrnite stran
ATC code: S01E E04 
Oznaka ATC: S01E E04
• If you use drops in both eyes, repeat the steps for the other eye 
• Če uporabljate kapljice v obeh očesih, ponovite te korake tudi na drugem očesu.
A change in the colour of the skin around the eye may also occur. 
Lahko se pojavi tudi sprememba barve kože okrog oči.
Don't put in any more drops until it's time for the next regular dose. 
Kapljic ne vkapajte ponovno, dokler ne bo čas za naslednji redni odmerek.
The following adverse reactions are classified according to the following convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to<1/1,000), very rare <1/10,000), or not known (frequency cannot be estimated from the available data). 
Naslednji neželeni učinki so razvrščeni v skladu z naslednjim dogovorom: zelo pogosti (≥1/10), pogosti (≥1/100 do <1/10), občasni (≥1/1.000 do <1/100), redki (≥1/10.000 do <1/1.000), zelo redki (<1/10.000) ali neznana pogostnost (ni je mogoče oceniti iz razpoložljivih podatkov).
It may be used on its own or with other drops e.g. beta-blockers, which also reduce pressure. 
Uporablja se lahko samostojno ali z drugimi kapljicami, npr. z antagonisti receptorjev beta, ki tudi znižajo tlak.
Do not throw away medicine via wastewater or in household waste. 
Zdravila ne smete odvreči v odpadne vode ali med gospodinjske odpadke.
What TRAVATAN is and what it is used for 
Kaj je zdravilo TRAVATAN in za kaj ga uporabljamo
If you or your child receive more TRAVATAN than you should Rinse all the medicine out with warm water. 
Če ste vi ali vaš otrok prejeli večji odmerek zdravila TRAVATAN, kot bi smeli Izperite vse zdravilo s toplo vodo.
Before treatment is instituted, patients must be informed of the possibility of a permanent change in eye colour. 
Pred začetkom zdravljenja morate bolnika opozoriti na možnost trajne spremembe barve oči.
Women who are pregnant or attempting to become pregnant should exercise appropriate precautions to avoid direct exposure to the contents of the bottle. 
Nosečnice ali ženske, ki skušajo zanositi, morajo uporabljati ustrezne previdnostne ukrepe, da preprečijo neposreden stik z vsebino kapalnega vsebnika.
Women of child-bearing potential/contraception 
Ženske v rodni dobi/kontracepcija
One drop in the affected eye or eyes, once a day - in the evening. 
Ena kapljica v prizadeto oko ali obe očesi, enkrat na dan, zvečer.
The marketing authorisation holder Novartis Europharm Limited Vista Building 
Imetnik dovoljenja za promet z zdravilom Novartis Europharm Limited Vista Building
No dosage adjustment is necessary in these patients (see section 5.2). 
Prilagoditev odmerka pri teh bolnikih ni potrebna (glejte poglavje 5.2).
In a similar 3 month study in adult patients, these events occurred at an incidence of 11.4% and 0.0%, respectively. 
V podobni 3-mesečni študiji pri odraslih bolnikih sta se ta dva dogodka pojavila z incidenco 11,4 % oziroma 0,0 %.
The effect on IOP was seen after the second week of treatment and was consistently maintained throughout the 12 week period of study for all age groups. 
Učinek na očesni tlak je bil opazen po drugem tednu zdravljenja in se je ohranjal skozi celotno 12-tedensko obdobje študije pri vseh starostnih skupinah.
The long term effects on the melanocytes and any consequences thereof are currently unknown. 
Dolgoročni učinki zdravila na melanocite in njihove morebitne posledice še niso znani.
Do not use TRAVATAN if you are pregnant. 
Ne uporabljajte zdravila TRAVATAN, če ste noseči.
It works by reducing the pressure in the eye. 
Deluje tako, da zniža očesni tlak.
Other medicines and TRAVATAN Tell your doctor or pharmacist if you are taking or have recently taken or used any other medicines. 
Obvestite zdravnika ali farmacevta, če jemljete ali ste pred kratkim jemali ali uporabljali katero koli drugo zdravilo.
• After using TRAVATAN, keep the eyelid closed, apply gentle pressure by pressing a finger into the corner of the eye, by the nose (picture 4) for at least 1 minute. 
• Po uporabi zdravila TRAVATAN držite veko zaprto, nežno pritisnite s prstom na očesni kot ob nosu (slika 4) za vsaj 1 minuto.
If you or your child are using other eye preparations such as eye drop or eye ointment, wait for at least 5 minutes between putting in TRAVATAN and the other eye preparations. 
Če vi ali vaš otrok uporabljate tudi druga zdravila za oko, kot so kapljice za oko in mazilo za oko, počakajte vsaj 5 minut med uporabo zdravila TRAVATAN in drugih zdravil za oko.
Ask your doctor for advice before taking any medicine 
Posvetujte se z zdravnikom, preden vzamete katerokoli zdravilo.
You can usually carry on using the drops, unless the side effects are serious. 
Običajno lahko tudi ob neželenih učinkih nadaljujete z uporabo kapljic, razen če so resni.
TRAVATAN may gradually change the eye colour by increasing the number of melanosomes (pigment granules) in melanocytes. 
Zdravilo TRAVATAN lahko postopoma spremeni barvo oči, saj poveča število melanosomov (pigmentnih zrnc) v melanocitih.
Prostaglandins and prostaglandin analogues are biologically active materials that may be absorbed through the skin. 
Prostaglandini in analogi prostaglandinov so biološko aktivne snovi, ki se lahko absorbirajo skozi kožo.
In the unlikely event of coming in contact with a substantial portion of the contents of the bottle, thoroughly cleanse the exposed area immediately. 
V malo verjetnem primeru stika z večjim delom vsebine kapalnega vsebnika je treba nemudoma temeljito očistiti izpostavljeni predel.
If you could become pregnant you must use adequate contraception whilst you use TRAVATAN. 
Če bi lahko zanosili, morate uporabljati ustrezno kontracepcijsko zaščito med uporabo zdravila TRAVATAN.
While most of the plasma data across all studies was non-quantifiable, making statistical comparisons of systemic exposure across age groups unfeasible, the overall trend shows that plasma exposure to travoprost free acid following topical administration of TRAVATAN is extremely low across all age groups evaluated. 
Čeprav večine plazemskih podatkov iz vseh študij ni bilo mogoče kvantificirati, zaradi česar je bila statistična primerjava sistemskih izpostavljenosti med posameznimi starostnimi skupinami neizvedljiva, pa je splošni trend pokazal, da je plazemska izpostavljenost prosti kislini travoprosta po topikalni uporabi zdravila TRAVATAN pri vseh ovrednotenih starostnih skupinah izjemno nizka.
It is unknown whether travoprost from the eye drops is excreted in human breast milk. 
Ni znano, ali se travoprost iz kapljic za oko izloča v materino mleko.
TRAVATAN is used to reduce high pressure in the eye in adults, adolescents and children from 2 months old onward. 
Zdravilo TRAVATAN se uporablja za zniževanje zvišanega očesnega tlaka pri odraslih, mladostnikih in otrocih od 2 mesecev starosti naprej.
Do not stop taking TRAVATAN without speaking to your doctor. 
Ne prenehajte uporabljati zdravila TRAVATAN, ne da bi se pogovorili s svojim zdravnikom.
If you are concerned about changes in your breathing pattern when using TRAVATAN advise your doctor as soon as possible. 
Če ste zaskrbljeni zaradi sprememb dihanja med uporabo zdravila TRAVATAN, o tem čimprej obvestite svojega zdravnika.
Due to the low plasma concentrations and rapid elimination following topical dosing, the elimination half-life of active free acid in man could not be determined. 
Zaradi nizke plazemske koncentracije in hitrega izločanja zdravila po topikalnem odmerjanju ni bilo mogoče določiti razpolovne dobe izločanja aktivne proste kisline pri človeku.
Only use TRAVATAN for dropping in your or your child's eye(s). 
Zdravilo TRAVATAN uporabljajte le za vkapanje v svoje oko(oči) ali v oko(oči) vašega otroka.
What you need to know before you use TRAVATAN 
Kaj morate vedeti, preden boste uporabili zdravilo TRAVATAN
• TRAVATAN may rarely cause breathlessness or wheezing or increase the symptoms of asthma. 
• Zdravilo TRAVATAN lahko v redkih primerih povzroči težko dihanje ali piskanje v pljučih ali poveča simptome astme.
There are no data on the effects of TRAVATAN on human fertility. 
Ni podatkov o učinkih zdravila TRAVATAN na plodnost pri človeku.
Typically, the brown pigmentation around the pupil spreads concentrically towards the periphery in affected eyes, but the entire iris or parts of it may be become more brownish. 
Običajno se rjava barva okoli zenice v prizadetem očesu koncentrično razširi proti periferiji, vendar lahko postane šarenica v celoti ali delno bolj rjava.
TRAVATAN can be used in children from 2 months to < 18 years at the same dose as for adults. 
Zdravilo TRAVATAN se lahko uporablja pri otrocih od 2 mesecev do < 18 let starosti v istem odmerku kot pri odraslih.
Patients must be instructed to remove contact lenses prior to application of TRAVATAN and wait 15 minutes after instillation of the dose before reinsertion. 
Bolnikom svetujte, naj kontaktne leče odstranijo pred uporabo zdravila TRAVATAN in po uporabi počakajo še 15 minut, preden si jih spet vstavijo.
Changes in the eyelids including unusual hair growth or in the tissues around the eye have also been observed. 
Opazili so tudi spremembe v očesnih vekah, ki vključujejo nenavadno rast dlak na vekah ali tkivu okrog očesa.
Do not use TRAVATAN after the expiry date which is stated on the bottle and the box after “EXP”. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na kapalnem vsebniku in na škatli poleg oznake „EXP“.
Efficacy and safety data in the age group 2 months to < 3 years (9 patients) is limited (see section 5.1). 
Podatki o učinkovitosti in varnosti zdravila pri starostni skupini od 2 mesecev do < 3 let (9 bolnikov) so omejeni (glejte poglavje 5.1).
If blurred vision occurs at instillation, the patient must wait until the vision clears before driving or using machines. 
Če ima po vkapanju kapljic bolnik zamegljen vid, mora počakati, da se mu vid zbistri, preden sme voziti ali upravljati stroje.
In children < 3 years old that mainly suffer from PCG (primary congenital glaucoma), surgery (e.g. trabeculotomy/goniotomy) remains the first line treatment. 
Pri otrocih starosti < 3 let, ki imajo predvsem PCG (primarni kongenitalni glavkom), je zdravljenje prve izbire še vedno kirurški poseg (npr. trabekulotomija/goniotomija).